drugset / Trial / NCT02709473

The Effect of Propofol and Remifentanil Sequence on ED50 and ED95 of Rocuronium in Rapid Sequence Induction Anesthesia

NCT02709473

Phase 4 Completed 84 enrolled Ankara University
RandomizedParallel-groupQuadruple-blindScreening

Summary

Rapid sequence induction (RSI) is a well-known procedure to maintain a safe and rapid airway in patients especially at risk of aspiration. Propofol and rocuronium are generally used agents for RSI. However, the difficult airway scenarios are always valid for these patients, even without predictive signs of difficult airway. Therefore, it is important to decrease the rocuronium dose used in RSI to achieve a rapid recovery of a neuromuscular conduction with the aid of a reversal agent in case of difficult airway. The short acting opioids such as remifentanil may be helpful to reduce the dose of rocuronium in RSI.

Timeline

Start
2016-03
Primary completion
2016-03
Completion
2016-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Propofol Small molecule 2 mg/kg
Comparator Remifentanil Small molecule 2 ug/kg
Comparator Rocuronium Other / unclassified 0.8 mg/kg

Indications

No indication recorded.